İlknur ÇÖL MADENDAĞ, YUSUF MADENDAĞ, Mehmet AK, ERDEM ŞAHİN, Mefküre ERASLAN ŞAHİN

The effect of oral micronized progesterone on first trimester screening test markers and neonatal outcome

Objective: It was aimed to investigate whether or not nuchal translucency(NT) thickness, maternal serum free betahuman chorionic gonadotropin(β-hCG) and pregnancy-associated plasma protein-A(PAPP-A) levels may affected by the use of oral micronized progesterone(OMP) in first trimester pregnancies. Also we aimed to evaluate pregnancy outcome in pregnant women using OMP. Method: This study was performed retrospectively including 1192 pregnant women, between January 2015 and August 2017. Body mass index(BMI), maternal and gestational age, levels of maternal serum PAPP-A and free β-hCG, NT measurement and the crown–rump length(CRL), fetal sex, fetal birth weight, Apgar score 5thminute

Oral mikronize progesteronun ilk trimester tarama belirteçlerine ve yeni doğan sonuçlarına etkisi

Amaç: ilk trimester gebeliklerde kullanılan oral mikronize progesteronun (OMP), ilk trimester tarama belirteçleri olan; ense saydamlığı kalınlığı, anne serum beta-insan koryonik gonadotropin (β-hCG) ve gebelikle ilişkili plazma protein-A (PAPP-A) düzeylerine etki edip etmediğinin araştırılması amaçlandı. Ayrıca, OMP kullanan gebe kadınlarda yenidoğan sonuçlarını değerlendirmeyi amaçladık. Yöntemler: Bu çalışma Ocak 2015-Ağustos 2017 tarihleri arasında 1192 gebe kadın dahil olmak üzere retrospektif olarak yapıldı. Vücut kitle indeksi (VKİ), maternal ve gestasyonel yaş, anne serum PAPP-A ve serbest β-hCG düzeyleri, ense saydamlığı ve ölçümü baş-popo uzunluğu (CRL) ölçümü, fetal cinsiyet, fetal doğum ağırlığı, Apgar skoru 5.dakika

PDF

___

1. Alldred SK, Takwoingi Y, Guo B, et all. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening. Cochrane Database of Systematic Reviews 2017: 3.

2. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75821 pregnancies: results and estimation of the potential impact of individual riskorientated two-stage first-trimester screening. Ultrasound Obstet Gynecol. 2005; 25: 221–6.

3. Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod. 2001; 16: 501–1504.

4. Walch KT, Huber JC. Progesterone for recurrent miscarriage: truth and deceptions. Best Pract Res Clin Obstet Gynaecol. 2008; 22: 375-89.

5. Sotiriadis A, Papatheodorou S, Makrydimas G. Threatened miscarriage: evaluation and management. Brid Med J. 2004; 329: 152.

6. Czajkowski K, Sienko J, Mogilinski M, et all. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril. 2007; 87: 613.

7. Weiss JL, Malone FD, Vidaver J, et al. Threatened abortion: a risk factor for poor pregnancy outcome, a population-based screening study. Am J Obstet Gynecol 2004; 190: 745.

8. Alp M, Diclehan O. Tekrarlayan spontan abortusları olan çiftlerde genetik araştırmalar. Dicle Tıp Derg. 2006; 33: 71-80.

9. Dunn CL, Kelly RW, Critchley HO. Decidualization of the human endometrial stromal cell: an enigmatic transformation. Reprod Biomed Online. 2003;7: 151.

10. Turgal M, Aydin E, Ozyuncu O. Effect of micronized progesterone on fetal‐placental volume in first‐trimester threatened abortion. J Clin Ultrasound. 2017; 45: 14-9.

11. Wang J, Liu S, Qin HM, Zhao Y, Wang XQ, and Yan Q. Pregnancy-associated plasma protein A up-regulated by progesterone promotes adhesion and proliferation of trophoblastic cells. Int J Clin Exp path. 2014; 7: 1427- 37.

12. Giorlandino C, Cignini P, Padula F, et all. Effects of exogenous progesterone on fetal nuchal translucency: an observational prospective study. Am J Obstet Gynecol. 2015; 212: 335-e1.

13. Keçecioğlu M, Tokmak A, Keçecioğlu TS, et all. Does progesterone therapy increase nuchal translucency in women with threatened miscarriage? Ginekol pol. 2016; 87: 390-4.

14. Kalem MN, Kalem Z, Bakırarar B, Ergün A, Gürgan T. The effect of progesterone use in the first trimester on fetal nuchal translucency. J Turk Ger Gynecol Assoc. 2018; 19: 29.